In 2020, Pandit-Taskar N et al. [62] assessed the safety and utility of [89Zr]IAB22M2C, a radiolabeled minibody against tumor-infiltrating CD8-positive (CD81) T lymphocytes, for targeted imaging of CD81 T cells in cancer patients. This evidence concerns the gene CD81 and neoplasm.